Niacin
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Niacin: From Lipid Modification to Homozygous Familial Hypercholesterolemia
One-Sentence Summary
Niacin is an established lipid-modifying agent, though the supplied data lists no approved indication text. The TxGNN model predicts it may be useful for homozygous familial hypercholesterolemia (HoFH). Evidence is thin: 2 clinical trials and 20 publications were retrieved, but none shows niacin’s efficacy in HoFH.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed (all US license records have empty indication text) |
| Predicted New Indication | Homozygous familial hypercholesterolemia |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (the listed oral tablets are ANDAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Niacin lowers LDL-C, triglycerides and Lp(a) and raises HDL-C. It is thought to work by reducing hepatic VLDL/apoB production, through DGAT2 inhibition and the GPR109A receptor. Formal mechanism-of-action data is not available in the Evidence Pack, so this description comes from general lipid pharmacology.
HoFH is caused mainly by LDL-receptor deficiency. A mechanism that reduces apoB-containing lipoprotein production does not depend on receptor function, so niacin could plausibly serve as an add-on lipid-lowering agent in HoFH.
However, this link is inferred, not shown in HoFH patients:
- The TxGNN score is a model prediction only.
- The retrieved literature is mostly disease-level review material that mentions niacin at most as a non-statin option.
- Large outcome trials of niacin in general dyslipidemia populations, which are not among the supplied records, did not show added cardiovascular benefit.
- Niacin has tolerability limits, including flushing and hepatic and glycemic effects.
Clinical Trial Evidence
Neither trial tests niacin, and both were graded C (low relevance).
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03510715 | Phase 3 | Completed | 18 | Open-label study of alirocumab (a PCSK9 inhibitor) in children and adolescents with HoFH. Matches the disease but not the drug, so it only shows the current HoFH treatment landscape. |
| NCT03110432 | N/A | Completed | 1695 | German registry of very-high-cardiovascular-risk dyslipidemia patients eligible for PCSK9 inhibitors. Not HoFH-specific and no niacin exposure indicated. |
Literature Evidence
None of these publications reports niacin efficacy in HoFH.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24506448 | 2014 | Review | Expert Rev Cardiovasc Ther | Critical review of non-statin options (fibrates, ezetimibe, bile acid sequestrants, n-3 fatty acids, niacin) for residual risk and statin intolerance. |
| 26376908 | 2015 | Scientific statement | Arterioscler Thromb Vasc Biol | ATVB Council statement on non-statin LDL-lowering therapy. Notes that niacin monotherapy reduced CVD endpoints in placebo-controlled trials. |
| 24734312 | 2014 | PK interaction study | Pharmacotherapy | Studied lomitapide’s pharmacokinetic interactions with lipid-lowering drugs, including niacin, in the HoFH treatment setting. |
| 26370207 | 2015 | Review | Drugs | Challenges in diagnosing and treating HoFH, a disease with severely elevated LDL-C and early cardiovascular risk. |
| 25257073 | 2014 | Review | Atheroscler Suppl | What current HoFH care (apheresis and lipid-lowering drugs) achieves, and the unmet needs. |
| 27797643 | 2016 | Review | Metab Syndr Relat Disord | Modern management of familial hypercholesterolemia, covering both HoFH and heterozygous forms. |
| 23959229 | 2013 | Review | Nat Rev Cardiol | Lipid-modifying pharmacotherapies beyond statins for severe hypercholesterolemia and mixed dyslipidemia. |
| 36422206 | 2022 | Review | Medicina (Kaunas) | Literature analysis of familial hypercholesterolemia diagnostics and treatment options. |
| 23074505 | 2007 | Health technology assessment | Ont Health Technol Assess Ser | Evidence-based analysis of LDL apheresis for refractory homozygous and heterozygous FH. |
| 2912428 | 1989 | Clinical study | Arteriosclerosis | Drug regimens in children and adolescents with FH (30 heterozygous, 3 homozygous). |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA203899 | Niacin (Golden State Medical Supply) | Tablet, extended release | Not listed |
| ANDA203578 | Niacin (Amneal Pharmaceuticals) | Tablet, extended release | Not listed |
| ANDA204934 | Niacin (Macleods Pharmaceuticals) | Tablet | Not listed |
| Not listed | THE SKIN HOUSE Vital Bright EyeCream (cosmetic) | Cream | Not listed |
| Not listed | DERLADIE LABORATOIRE PORE TIGHTENING AMPOULE (cosmetic) | Liquid | Not listed |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score and a plausible but inferred mechanism. The retrieved trials and publications contain no niacin-specific efficacy or safety data in HoFH. Niacin’s tolerability limits and the lack of added cardiovascular benefit in general dyslipidemia outcome trials also argue against advancing now.
To proceed, the following is needed:
- Package insert warnings and contraindications (blocking data gap), to allow safety screening
- Mechanism-of-action data from DrugBank and the approved indication text
- Niacin-specific HoFH evidence, such as case series, small trials, or use as an add-on to statins, ezetimibe, or PCSK9 inhibitors
- Comparison against current HoFH standards of care (PCSK9 inhibitors, lomitapide, LDL apheresis) to define any remaining role for niacin
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.